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 Chapter 19 
 Use of MicroRNAs in Personalized Medicine 
 Çiğir  Biray  Avci and  Yusuf  Baran 
 Abstract 
 Personalized medicine comprises the genetic information together with the phenotypic and environmental 
factors to yield healthcare tailored to an individual and removes the limitations of the “one-size-fi ts-all” 
therapy approach. This provides the opportunity to translate therapies from bench to clinic, to diagnose 
and predict disease, and to improve patient-tailored treatments based on the unique signatures of a 
patient’s disease and further to identify novel treatment schedules. 
 Nowadays, tiny noncoding RNAs, called microRNAs, have captured the spotlight in molecular biol-
ogy with highlights like their involvement in DNA translational control, their impression on mRNA and 
protein expression levels, and their ability to reprogram molecular signaling pathways in cancer. Realizing 
their pivotal roles in drug resistance, they emerged as diagnostic targets orchestrating drug response in 
individualized therapy examples. 
 It is not premature to think that researchers could have the US Food and Drug Administration 
(FDA)-approved kit-based assays for miRNA analysis in the near future. We think that miRNAs are ready 
for prime time. 
 Key words  miRNAs ,  Personalized medicine ,  Pharmacogenomics 
1  Introduction 
 Pharmacogenomics investigations have emphasized genes that 
contribute to an individual patient’s drug sensitivity, resistance, 
and toxicity. It has also designated the causes of interindividual 
variations in the expression and function of many of the genes, 
including the roles of microRNAs, DNA methylation, copy num-
ber variations, and single-nucleotide polymorphisms. 
 In this chapter, we focus on miRNAs, 19–24-nucleotide non-
coding RNAs that function as gene regulators and have roles in 
countless cellular processes. We discuss how miRNAs, arranging 
the expression of pharmacogenomic-relevant genes, play a consid-
erable role in drug effi cacy and toxicity and have potential clinical 
refl ections for personalized medicine. 
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2  MicroRNA Pharmacogenomics 
 The National Cancer Institute of the National Institutes of Health, 
USA, defi ned “personalized medicine” in 2011 as a form of healthcare 
that considers information about a person’s genes, proteins, and 
environment to prevent, diagnose, and treat disease [ 1 ]. 
Developments in the fi eld of pharmacogenomics are not only due 
to better sequencing technology but also stem from gene expres-
sion alterations on the account of regulatory elements and epigen-
etic variations that occur in response to the environment. In the 
realm of RNA, these modulations usually result from two compre-
hensive components: fi rst, the direct regulatory impact of miscel-
laneous forms of noncoding RNA (hnRNA, microRNA, etc.) that 
have the capacity to modulate expression by interacting with DNA 
regulatory sequences in promoters or in different regions of target 
genes and, second, the environmentally stimulated chemical mod-
ulation of DNA nucleotides, principally by cytosine methylation. 
 The application of genomics in personalized medicine includes 
its potential to improve risk assessment, diagnosis, prognosis, and 
treatment. Classical examples of current genomic investigation in 
personalized medicine are (1) BRCA1/2 testing for risk assess-
ment of breast cancer, (2) gene expression profi les to diagnose 
breast cancer subtypes [ 2 ], (3) number of trinucleotide repeats 
predicting the seriousness of Fragile X syndrome [ 3 ], and 
(4) Herceptin ® (trastuzumab) management that is restricted using 
a companion diagnostics to women protecting from HER2-
positive breast cancer [ 4 ,  5 ] and CYP2C19 variants associated with 
minimized clopidogrel response [ 6 ]. 
 Metabolism of xenobiotics (drugs, environmental chemicals, 
carcinogens) and endobiotics (steroids, bile acids, and fatty acids) 
are catalyzed by essential enzymes called P450s that are transcrip-
tionally regulated by nuclear receptors. 
 Cytochrome P450s and nuclear receptors, such as CYP1B1, 
CYP2A3 (rat), CYP2E1, CYP3A4, CYP24A1, pregnane X recep-
tor (PXR), vitamin D receptor (VDR), peroxisome proliferator- 
activated receptor γ (PPARγ), RXRα (rat), hepatocyte nuclear 
factor 4α (HNF4α), estrogen receptor α (ERα), and human gluco-
corticoid receptors (GR) that are regulated by miRNAs, were stud-
ied in a wide range of studies [ 7 ]. 
3  Diagnostic and Prognostic Implementations: MicroRNA Signatures 
in Solid Tumors 
 Potential links to the etiology of a disease have been obtained from 
sets of differentially expressed mRNAs and miRNAs (expression 
signatures) acquired via expression profi ling of whole tumor 
 samples (Table  1 ).
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 In colorectal cancer, 18 miRNA signatures ( see  Note 1 ) are 
responsible for subtype classifi cation like microsatellite stable 
(MSS) vs. microsatellite instable (MSI-high) [ 18 ,  19 ]. Additionally, 
miR-320 and -498 signatures are accountable for recurrence-free 
survival in stage II MSS cases [ 18 ]. 
 The prevailing oncomir in colorectal cancer is miR-21 involved 
in diagnostic and prognostic applications. This worthy miRNA 
plays a key role in response to neoadjuvant chemoradiotherapy in 
advanced rectal cancer [ 20 ], recurrence-free survival in stage II 
colon cases [ 21 ], recurrence-free survival in all-comers [ 22 ], 
recurrence- free and overall in all-contributors [ 23 ], and overall 
survival in all-contributors [ 24 ]. 
 In lung cancer, miRNA signatures are miscellaneous. There are 
34 miRNA signatures ( see  Note 2 ) responsible for prediction of 
subtype classifi cation into adenocarcinoma (AdCa) vs. squamous 
cell carcinoma (SCC) in male smokers [ 25 ]. Signatures of the 
 miRNAs let-7a and miR-221, 137, -182, and -372 are essential for 
 Table 1 
 Diagnostic and prognostic applications of miRNA signatures in solid tumors 
 Signature in 
breast cancer  Clinical application(s)  References 
 miR-7, -128a, 
-210, -516-3p 
 Disease progression (distant metastasis) of estrogen receptor+ 
lymph node− cases 
 [ 8 ] 
 miR-30a-3p, 
-30c, -182 
 Response to adjuvant tamoxifen in advanced ER+ cases  [ 9 ] 
 miR-128a, -135a, 
-767-3p, 
-769-3p 
 Recurrence-free survival in ER+ cases  [ 10 ] 
 miR-27b, -30c, 
-144, -150, 
-210, -342 
 Recurrence-free survival in ER− cases  [ 10 ] 
 miR-21, -181a  Recurrence-free and overall survival in all-comers  [ 11 ] 
 miR-21, -210, 
-221, -222 
 Recurrence-free and overall survival in ER−, progesterone 
receptor−, human EGF receptor 2− cases 
 [ 11 ] 
 mir-21  Response to neoadjuvant trastuzumab treatment, recurrence-free 
survival in stage I/II all-comers, overall survival in all-participants 
 [ 12 – 14 ] 
 miR-205  Disease recurrence and overall survival in ER−, progesterone 
receptor−, HER2− cases 
 [ 15 ] 
 miR-210  Disease progression (distant metastasis) in ER− lymph node– cases, 
disease progression (distant metastasis) in ER− PR− HER2− LN− 
cases, recurrence-free and overall survival in all attendants, 
response to tamoxifen in ER+ cases 
 [ 8 ,  16 ,  17 ] 
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recurrence-free and overall survival in non-small-cell lung cancer 
(NSCLC) cases [ 26 ]. 
 In the literature, it was shown that nineteen miRNA signature 
( see  Note 3 ) can play a major role in prediction of overall survival 
in SCC cases [ 27 ], and let-7e and miR-34a, -34c-5p, -25, and 
-191 signatures have a role in estimation of overall survival in male 
smoker SCC cases [ 25 ]. 
 According to the studies concerning lung cancer let-7a has 
prognostic factors alone like overall survival in NSCLC [ 28 ] and 
AdCa cases [ 29 ], miR-21 has prognostic value in overall survival in 
NSCLC [ 30 ] and SCC cases [ 31 ], and miR-34a is an important 
marker for recurrence-free and overall survival in NSCLC cases 
[ 32 ]. The miRNA miR-155 has crucial role in overall survival in 
AdCa cases [ 29 ], and miR-205 distinguishes AdCa from SCC 
[ 33 – 35 ]. 
 These abovementioned issues contain important data for appli-
cations of miRNA signatures especially in solid tumors, but they 
are just preclinical data, and further validation and understanding 
of what these signatures refl ect are required for converting them to 
approved approaches. 
4  Correlation of Drug Resistance with Deregulation of MicroRNA Expression 
 Aberration of miRNA expression in malignant tumor cells is consid-
erably observed and can be triggered by three distinct mechanisms:
  1.  Location of miRNAs in cancer-associated tissue. 
  2.  Genomic region or at fragile sites, epigenetic regulation of 
miRNA genes. 
  3.  Abnormalities in miRNA processing genes and proteins [ 36 ]. 
 Changes in expression levels of miRNAs affect numerous target 
mRNAs and for this reason multiple proteins pioneering the diver-
sity in the chemosensitivity of cancer cells through miscellaneous 
cellular processes. Cellular response to anticancer agents shifted by 
most of the miRNAs by means of survival signaling pathways and 
programmed cell death response modulation [ 37 ]. Additionally, 
there are reports about miRNAs affecting mechanisms such as 
drug targets and DNA repair systems [ 38 ,  39 ]. Ultimately, miR-
NAs also have duties in the regulation of drug metabolism by 
 regulating the expression of drug-metabolizing enzymes and drug 
transporters [ 40 ]. 
 Numerous studies have shown the effect of specifi c microR-
NAs on factors encompassed in apoptosis and survival pathways 
impressing anticancer drug sensitivity and resistance (Table  2 ).
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 Examples could be multiplied according to recent studies in 
literature due to the loss of, increased, or decreased expressions of 
22 specifi c miRNAs ( see  Note 4 ) targeting genes ( see  Note 4 ) 
involved in apoptosis and survival pathways affecting anticancer 
drug sensitivity in various cancer types including breast, cervical, 
prostate, colorectal, colon, cholangiocarcinoma, T-cell leukemia, 
and osteosarcoma [ 7 ]. 
 The mRNA, miR-21, is important in chemoresistance. 
Increased expression of miR-21 prevents gemcitabine-induced 
apoptosis targeting PTEN in cholangiocarcinoma [ 47 ] and 
unknown molecules in pancreatic cancer [ 48 ]. Overexpression of 
miR-21 triggers increased resistance to VM-26 in glioblastoma 
[ 49 ] and topotecan in breast cancer [ 50 ] by targeting LRRFIP1 
and Bcl-2, respectively. Contrariwise, the expression inhibition of 
miR-21 increased the sensitivity to TRAIL-induced apoptosis in 
glioma [ 51 ]. Interestingly, it increased the expression protected 
against temozolomide-induced apoptosis via targeting Bax in glio-
blastoma [ 52 ] and arsenic trioxide-induced apoptosis by targeting 
PDCD4 in chronic myeloid leukemia [ 53 ] and also prevented 
apoptosis induced by arabinosylcytosine by targeting PDCD4 in 
acute myeloid leukemia [ 54 ]. 
 Table 2 
 Some important miRNAs and drug resistance/effect 
 Expression 
change  miRNA 
 Resistance/
sensitivity  Drug 
 Target 
gene 
 Cancer or cell 
line  Reference 
 Upregulation 
of expression 
 Let-7a  Resistance  IFNγ  Caspase-3  Hepatocellular 
carcinoma 
 [ 41 ] 
 Doxorobicin  Human 
squamous 
 Paclitaxel 
 Overexpression  Let- 7a/b  Radio-
sensitization 
 -  RAS  Lung cancer  [ 42 ] 
 Overexpression  Let-7g  Resistance  -  RAS  Lung cancer  [ 42 ] 
 Increased 
expression 
 miR-1  Sensitivity  Doxorobicin  Mcl-1  NSCLC cells  [ 43 ] 
 Overexpression  miR- 
15b/16 
 Sensitivity  Several drugs  Bcl-2  Gastric cancer  [ 44 ] 
 Increased 
expression 
 miR-27a  Resistance  Paclitaxel  HIPK2  Ovarian cancer  [ 45 ] 
 Overexpression  miR- 
27a/451 
 Resistance  Vinblastine 
 Doxorubicin 
 MDR1  Ovarian cancer 
 Cervical cancer 
 [ 46 ] 
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5  Drug Resistance miRNA Pharmacogenetics Association 
 The expression levels of mature miRNAs may be affected by two 
pathways: sequence variations in miRNA regions and miRNA- 
processing pathways [ 55 ,  56 ]. This issue is discussed in more detail 
in Chapter  18 . The pharmacogenetic analysis of miRNAs may rep-
resent a revolutionary area of investigation for predicting treat-
ment response or chemoresistance [ 57 ]. These alterations are 
owing to single-nucleotide polymorphisms (SNPs [ 56 ]). SNPs can 
occur in three different ways: (1) polymorphisms affecting miRNA 
biogenesis, by modulating the transcription of pri-miRNA or pre- 
miRNA processing and maturation; (2) polymorphisms in miRNA 
target sites; and (3) polymorphisms altering epigenetic regulation 
of miRNA genes [ 56 ] (Table  3 ).
6  MicroRNAs in Cancer Stem Cells: Association with Drug Resistance 
 Recently, it has become clear that miRNAs can play a pivotal role 
in the drug resistance of cancer cells and cancer stem cells. Drug 
resistance in cancer stem cells inserts another viewpoint to the 
challenge of drug resistance in cancer. Cancer stem cell hypothesis 
states that when not all cancer stem cells from a tumor are extir-
pated, the tumor will always reoccur [ 61 ] (Table  4 ).
 The fact that cancer stem cells are often found to be resistant 
to one or multiplexed drugs increases the complexity for successful 
cancer cures. For this reason, it is extremely important to explore 
occasions to selectively target the cancer stem cell population of a 
tumor. Selective killing of cancer stem cells would properly enhance 
patient outcome by preventing metastasis and recurrence of the 
 Table 3 
 MicroRNAs and drug relationships 
 miRNA  Change 
 Target 
gene 
 Cancer or 
cell line  Result  Reference 
 miR-24  C to T  DHFR 
3′UTR 
 DG44 
cells 
 Resistance to methotrexate  [ 39 ] 
 miR-206b  C to T  ER-alpha  Breast 
cancer 
 Sensitivity to endocrine therapy  [ 58 ] 
 miR-519c  Deletion  ABCG2 
3′UTR 
 Colon 
cancer 
 Inhibition of repression/
multidrug resistance 
 [ 59 ] 
 pri-miR- 26a1/
pri-miR- 100 
 Several 
SNPs 
 –  Colon 
cancer 
 Longer time to progression after 
5-fl uorouracil or irinotecan 
treatment 
 [ 60 ] 
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primary tumor. In the last years, some encouraging studies have 
been succeeded in this research fi eld, with distinct molecules devel-
oped to specifi cally kill cancer stem cells, such as monoclonal anti-
bodies targeting leukemic stem cell marker CD44 [ 67 ] or drugs 
like nigericin and abamectin that inhibit cancer stem cell growth 
[ 68 ] or gene therapy [ 69 ,  70 ]. 
 There are a lot of studies concerning with this issue. The 
miRNA, miR-34, is directly regulated by p53 and downregulated 
in most tumors, which suggests a common drug resistance via tar-
geting Notch, HMGA2, and Bcl-2 in cancer stem cells that lack 
p53 expression [ 62 ]. 
 Upregulation of miR-125b increases the rate of proliferation 
and decreases sensitivity to ATRA-induced apoptosis by targeting 
Bmf in glioma stem cells [ 102 ]. 
 Overexpression of miR-140 elevates the resistance against 
methotrexate and 5-FU HDAC4 osteosarcoma and colon cancer 
stem cells [ 65 ]. 
 Upregulation of miR-215 downregulates dihydrofolate reduc-
tase (DHFR) and thymidylate synthase (TS) which in turn leads to 
increased resistance against methotrexate and tomudex in osteo-
sarcoma and colon cancer stem cells, respectively [ 65 ,  71 ]. 
7  MicroRNAs as Drugs 
 Rukov et al. reported that attempts are in progress to improve 
miRNA-based drugs, either in the form of miRNA mimics, ampli-
fying the effect of a miRNA, or miRNA inhibitors, fundamentally 
suppressing the effect of a miRNA [ 7 ]. MicroRNA drugs have the 
 Table 4 
 miRNAs in cancer stem cells: Association with drug resistance 
 miRNA  Characteristics  Targets  Tumor model  Reference 
 miR-34  Regulated by p53, 
downregulated in most 
tumors/drug resistance 
 Notch, 
HMGA2,Bcl-2 
 Cancer stem cells lacking 
p53 gene expression 
 [ 62 ] 
 miR- 
125b 
 Decreased sensitivity of 
ATRA- induced apoptosis 
via upregulation 
 Unknown  Glioma  [ 63 ,  64 ] 
 miR- 140  Methotrexate and 5-FU 
resistance increased via 
upregulation 
 HDAC4  Colon and osteosarcoma 
stem cells 
 [ 65 ] 
 miR- 215  Methotrexate and tomudex 
resistance increased by 
downregulation of 
DHFR and TS 
 DHFR, TS  Osteosarcoma and colon 
cancer stem cells 
 [ 66 ] 
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benefi t that one miRNA may target and modify the expression of 
several genes with different roles in the same pathway. The most 
developed miRNA drug to date is a miRNA inhibitor targeting 
miR-122 in liver to treat hepatitis C virus (HCV [ 72 ]). One issue 
as such drugs approach clinical use is testing for interactions 
between the novel miRNA drugs and traditional drugs already in 
the market. The connection from miRNAs to drugs allows 
Pharmaco-miR to predict default interactions between novel 
miRNA drugs and more traditional drugs, which can then be 
tested experimentally [ 7 ]. For example miR-122 is estimated to 
target estrogen receptor 1 (ESR1), whose gene product is neces-
sary for the important drug families of estrogens (e.g., estradiol) 
and antiestrogens (e.g., tamoxifen). If this predicted target is func-
tional, treating patients for HCV with miR-122 may cause adverse 
drug effects if the patient is also undergoing treatment with estro-
gens or antiestrogens. 
 In recent years, an increasing number of papers describe a link 
between miRNAs and drug function through deregulation of 
pharmacogenomic-relevant genes. These studies are mainly per-
formed in cancer cell lines and mainly describe chemoresistance. 
Drug toxicity studies and studies on drug metabolizers are remark-
ably rare. Also, many studies report miRNA deregulation in drug- 
resistant cells but fail to identify the miRNA target effector genes. 
The lack of such studies highlights how elusive it can be to link 
miRNA expression with the connection between genes and drug 
effi cacy/toxicity. Pharmaco-miR is a web server designed to help 
in defi ning such interactions between miRNAs, target genes, and 
associated drugs by complementary of the pioneering resources 
on miRNA targeting and pharmacogenomics. The outcome usu-
ally comprises a miRNA pharmacogenomic set consisting of a 
miRNA, a target gene, and a drug commented in the literature as 
being linked with the target gene. Pharmaco-miR is thus a useful 
tool when predicting the effect of miRNAs on drug effi cacy and 
toxicity or when developing hypothesis within miRNA pharma-
cogenomics. Identifi cation of miRNA pharmacogenomic sets 
makes it possible to outline potential mechanisms for miRNA–
drug interactions when planning experiments and assists in the 
interpretation of results. As the fi eld of miRNA pharmacogenom-
ics matures, Pharmaco-miR can be extended to collect relevant 
information within the fi eld and allow searches specifi cally for 
miRNA pharmacogenomic sets, where the full set has been inves-
tigated in a pharmacogenomic context [ 7 ]. 
 According to the National Center for Toxicological Research’s 
2011–2012 annual report, new biomarkers of liver damage are 
needed to improve detection of injury in animals and humans. 
A genomics approach was used on urine samples of rats treated 
with drugs and chemicals that cause liver injury. Several urinary 
miRNAs (also called epigenetic biomarkers) were identifi ed that 
may serve as predictive biomarkers of hepatotoxicity. 
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 MicroRNAs are differently expressed in diseases, and they have 
crucial responsibilities in diverse biological pathways. Notwithstanding 
alteration of DNA methylation or histone modifi cations, deregu-
lated miRNA expression patterns of tumor cells have been described 
as colliding with drug response. Approaches to arrange the expres-
sion of chosen miRNAs have partly led to intriguing developments 
of chemotherapy response. 
 MicroRNAs are potential targets of therapeutics. The arrange-
ment of miRNA levels covers a wide spectrum of technologies 
from gene therapy to antisense therapy. Targeting miRNAs for 
therapy could be an emerging fi eld, although there are many 
obstacles to be overcome: stability, convenient in vivo delivery sys-
tems, and selectivity. An individual miRNA could regulate several 
genes and pathways simultaneously suggesting that miRNA modu-
lation could be powerful. However, attention must be paid to the 
possibility that miRNA manipulation may cause adverse infl uences, 
for the reason that each miRNA target has not been identifi ed. 
Chiefl y there are two strategies to target miRNA expression: by 
blocking the expression of an oncomiR or by re-expression of a 
tumor-suppressor miRNA, or by targeting the genes involved in 
their transcription and processing. Anti-miRNA oligonucleotides 
(AMOs) [ 73 – 76 ], locked nucleic acids (LNA) [ 77 – 81 ], small- 
molecule inhibitors (SMIRs), miRNA sponges or decoys [ 71 ,  82 , 
 83 ], nanoparticles [ 84 – 86 ], and miRNA mimics and adenovirus- 
associated vectors (AAV) [ 87 – 90 ] are the current ways to target 
miRNAs as drugs. 
 There is growing evidence that diagnostic and prognostic 
miRNA signatures are indispensable in tumor classifi cation and 
treatment protocols. Differences in individual gene expressions 
stimulated the interest of global miRNA expression studies in 
human diseases that exposed modest variations between normal 
and tumor tissues [ 64 ,  91 – 93 ]. For instance, in tumor tissues, 
miR-125b and miR-145 are mostly determined at lower levels 
while miR-21, miR-155, and miR-210 at higher levels [ 50 ,  94 –
 96 ]. But of course, there are slight differences in miRNA expres-
sions, and further studies are needed to detect alterations in the 
signaling pathways and enlighten treatment response [ 95 ,  97 ]. 
There are high numbers of studies demonstrating miRNA signa-
tures and their prognostic value correlation [ 53 ,  91 ,  98 ,  99 ]. 
 Studies in CRC cell lines declared that mRNA and miRNA 
signatures could improve prediction of treatment response over 
K-Ras mutation status alone and thus inform patient eligibility to 
anti-EGFR-based treatments [ 100 ,  101 ]. Ragusa et al. reported on 
using cetuximab-sensitive and -resistant CRC cell lines to profi le 
miRNA expression, and they suggested three miRNA signatures 
for estimating treatment response to cetuximab [ 101 ]. Two of 
these miRNAs, let-7b and let 7e, were found to be negative regula-
tors of K-Ras expression. Several studies showed the importance of 
let-7’s role in a poor outcome of cetuximab-treated metastatic 
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CRC patients [ 102 ,  103 ]. Also, let-7a-mediated regulation of 
K-Ras expression was fi rst described in lung cancer [ 104 ]. 
 The most important problem in the majority of the cancer 
cases is a lack of targeted therapy. MicroRNA signature analyses 
are indispensable in every step of therapy approach like tumor 
aggressiveness and resistance to treatment in almost every type of 
cancer affecting different gene expressions like EGFR and K-Ras 
and in several signaling pathways [ 105 – 107 ]. These studies also 
identifi ed the organ site of carcinomas of unknown primary origin 
[ 108 ,  109 ]. 
 Additionally, miRNA signatures are crucial in blood samples 
of patients to detect diseases earlier and monitor progression of 
diseases in a noninvasive way after treatment [ 110 – 113 ]. 
 Global miRNA profi ling pioneered to improve disease man-
agement from bench to clinical applications. 
8  Conclusion 
 MicroRNAs are potential providers of drug response prediction. 
MicroRNAs are also the headliners of drug resistance and pharma-
cological drug response dilemma and conducives of drug dosage 
tailoring and inhibitors of adverse drug reactions that procreate 
personalized therapy. 
 Complicated dynamic natured networks between diagnostic, 
prognostic, and therapeutic miRNAs and their targets are com-
plex, and in vitro studies alone may be improper to estimate 
miRNA signifi cance related with early detection, progression, 
recurrence, and treatment response in vivo. 
 In the light of these novel fi ndings, more studies should be 
conducted in order to demonstrate the utilization of these tiny but 
indispensable molecules in diagnosis and treatment of various dis-
eases: a dream could be realized. Individualizing current anticancer 
regimens by predicting the potential intrinsic/acquired resistance 
and future therapeutic strategies to get over resistance, including 
specifi c targeting of miRNA (via mimics or antagomirs) is very 
important. Also these regimens target synergistic interaction with 
anticancer agents. These regimens use the modulation of expres-
sion of key proteins in different molecular mechanisms involved in 
drug activity. 
9  Notes 
  1.  In colorectal cancer, miR-142-3p, -144, -151, -212, -17, -20, 
-25, -32, -92, -93, -106a, -125a, -155, -191, -192, -203, -215, 
and -223 are responsible for subtype classifi cation like MSS vs. 
MSI-high. 
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  2.  MicroRNA signatures such as let-7a, -7b, -7c, -7d, -7e, -7f, 
-7g, and -7i and miR-16, -17, -19b, -20a, -26a, -26b, -29a, 
-29b, -29c, -30b, -30d, -98, -103, -106a, -106b, 107, -146b-
5p, -181a, -191, -195, -453, -491-5p, -498, -509-3p, -654-
5p, and -663 are responsible for the subtype classifi cation of 
AdCa vs. SCC. 
  3.  MicroRNA signatures, such as let-7e and miR-17-5p, -20a, 
-20b, -21, -93, -106a, -106b, -126, -146b, -155, -182, -183, 
-191, 200a, -200c, -203, -210, and -224, have a major role in 
the prediction of the overall survival in SCC cases. 
  4.  Specifi c miRNAs such as miR-27b, -29a/181a/221, -34a, 
-98, -122, -125b, -140, -143, -148a, -155, -192/215, -199a-
3p, -200c, -204, -205, -212, -214, -221/222, -320, -328, 
-451, and -512 targeting genes (such as CYPIB1, SIRT1, 
HMGA2, Cyclin G1, BAK1, HDAC4, ERK5, MSK1, PXR, 
FOXO3a, TS, mTOR, C-Met, TUBB3, Mcl-1, HER3, PED, 
PTEN, P27, ERα, Bcl-2, ABCG2, and CSA) are involved in 
apoptosis and survival pathways affecting anticancer drug sen-
sitivity in various cancer types, including breast, cervical, pros-
tate, colorectal, colon, cholangiocarcinoma, T-cell leukemia, 
and osteosarcoma. 
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